Research Publications

Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.

Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, Jackman D, Sarembock IJ, Topol EJ

Failing the public health--rofecoxib, Merck, and the FDA.

Topol EJ

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes.

Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM

ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).

Cura FA, Roffi M, Pasca N, Wolski KE, Lincoff AM, Topol EJ, Lauer MS, Global Use of Strategies to Open Occluded Arteries V investigators

Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization.

Ellis SG, Bajzer CT, Bhatt DL, Brener SJ, Whitlow PL, Lincoff AM, Moliterno DJ, Raymond RE, Tuzcu EM, Franco I, Dushman-Ellis S, Lander KJ, Schneider JP, Topol EJ

An ensemble method for gene discovery based on DNA microarray data.

Li X, Rao S, Zhang T, Guo Z, Zhang Q, Moser KL, Topol EJ

Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I.

Kaul P, Armstrong PW, Chang WC, Naylor CD, Granger CB, Lee KL, Peterson ED, Califf RM, Topol EJ, Mark DB

Association of race with complications and prognosis following acute coronary syndromes.

Asher CR, Moliterno DJ, Bhapkar MV, McGuire DK, Rao SV, Holmes DR, Newby LK, Bates ER, Topol EJ, SYMPHONY and 2nd SYMPHONY Investigators

Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.

Saw J, Lincoff AM, DeSmet W, Betriu A, Rutsch W, Wilcox RG, Kleiman NS, Wolski K, Topol EJ, REPLACE-2 Investigators

Invisible showers.

Topol EJ